

Edgar Filing: BIO-TECHNE Corp - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 101.19					<u>(2)</u>	10/26/2026	Common Stock	3,985
Stock Option (right to buy)	\$ 87.34					10/29/2016	10/28/2025	Common Stock	4,260
Stock Option (right to buy)	\$ 91.78					10/30/2014	10/30/2024	Common Stock	4,000
Stock Option (right to buy)	\$ 87.39					10/31/2013	10/30/2023	Common Stock	4,000
Stock Option (right to buy)	\$ 66.9					10/25/2012	10/24/2022	Common Stock	5,000
Stock Option (right to buy)	\$ 70.35					10/27/2011	10/26/2021	Common Stock	5,000
Stock Option (right to buy)	\$ 61.46					10/28/2010	10/27/2020	Common Stock	5,000
Stock Option (right to buy)	\$ 63.03					10/29/2009	10/28/2019	Common Stock	5,000

Stock Option (right to buy)	\$ 65.47	10/23/2008	10/22/2018	Common Stock	5,000
Stock Option (right to buy)	\$ 66.59	10/25/2007	10/24/2017	Common Stock	5,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HOLBROOK KAREN A 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413		X		

Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Karen A. Holbrook pursuant to Power of Attorney previously filed.

12/01/2016

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.54 to \$106.90 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (2) The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.